Research Article

**In Silico Investigation of Potential mTOR Inhibitors from Traditional Chinese Medicine for Treatment of Leigh Syndrome**

Kuan-Chung Chen, Wen-Yuan Lee, Hsin-Yi Chen, and Calvin Yu-Chian Chen

1 School of Pharmacy, China Medical University, Taichung 40402, Taiwan
2 School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan
3 Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
4 Department of Neurosurgery, China Medical University Hospital, Taichung 40447, Taiwan
5 Human Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
6 Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 40402, Taiwan

Correspondence should be addressed to Calvin Yu-Chian Chen; ycc929@mit.edu

Received 23 February 2014; Revised 5 March 2014; Accepted 5 March 2014; Published 23 June 2014

A recent research demonstrates that the inhibition of mammalian target of rapamycin (mTOR) improves survival and health for patients with Leigh syndrome. mTOR proteins can be treated as drug target proteins against Leigh syndrome and other mitochondrial disorders. In this study, we aim to identify potent TCM compounds from the TCM Database@Taiwan as lead compounds of mTOR inhibitors. PONDR-Fit protocol was employed to predict the disordered disposition in mTOR protein before virtual screening. After virtual screening, the MD simulation was employed to validate the stability of interactions between each ligand and mTOR protein in the docking poses from docking simulation. The top TCM compounds, picrasidine M and acerosin, have higher binding affinities with target protein in docking simulation than control. There have H-bonds with residues Val2240 and 𝜋 interaction with common residue Trp2239. After MD simulation, the top TCM compounds maintain similar docking poses under dynamic conditions. The top two TCM compounds, picrasidine M and acerosin, were extracted from *Picrasma quassioides* (D. Don) Benn. and *Vitex negundo* L. Hence, we propose the TCM compounds, picrasidine M and acerosin, as potential candidates as lead compounds for further study in drug development process with the mTOR protein against Leigh syndrome and other mitochondrial disorders.

1. Introduction

Leigh syndrome is a rare fatal prototypical mitochondrial disorder for children [1, 2]. It is a serious disorder for children as it can lead to death within the first few years of life [3, 4]. Recently, increasing numbers of pathogeneses for diseases have been identified [5, 6] to identify the potential target proteins for drug design [7–10]. A recent research demonstrates that the inhibition of mammalian target of rapamycin (mTOR) improves survival and health for patients with Leigh syndrome [11]. The mTOR proteins can be treated as drug target proteins against Leigh syndrome and other mitochondrial disorders [12–14]. Nowadays, compounds extracted from traditional Chinese medicine (TCM) have shown their potential to be lead compounds against cancers [15–17], diabetes [18], inflammation [19], metabolic syndrome [20], stroke [21, 22], viral infection [23, 24], and many different diseases [25, 26]. In this study, we aim to identify potent TCM compounds from the TCM Database@Taiwan [27] as lead compounds of mTOR inhibitors, in order to improve the development of TCM compounds. As structural disordered disposition in the protein may be the cause of side effect and decrease of occupancy for ligand to bind with target protein [28], PONDR-Fit protocol was employed to predict the disordered disposition in mTOR protein before virtual screening. After virtual screening, the
Table 1: Scoring functions of top candidates and Torin2 from TCM database screening.

| Name                          | Resource                                | -PLP1 | -PLP2 | Dock Score |
|-------------------------------|-----------------------------------------|-------|-------|------------|
| Picrasidine M                 | *Picrasma quassioides* (D. Don) Benn.   | 118.22| 104.11| 88.913     |
| Acerosin                      | *Vitex negundo* L.                      | 104.12| 108.76| 78.088     |
| Psychotrine                   | *Alangium lamarckii*                    | 107.12| 97.2  | 75.322     |
| 3,5,6-Trihydroxy-3',4',7-trimethoxyflavone | *Citrus medica* var. *sarcodactylis* (Noot.) Swingie | 106.07| 105.45| 73.906     |
| Torin2*                       | *Control.*                              | 115.23| 107.26| 55.507     |

*Control.

Table 2: H-bond occupancy for key residues of mTOR protein with Torin2 and top TCM compounds over 5000 ps of molecular dynamics simulation.

| Name          | H-bond interaction | Occupancy |
|---------------|--------------------|-----------|
| Torin2        | Lys2187:HZ3 /N31   | 2%        |
|               | Lys2187:HZ3 /N32   | 35%       |
|               | Glu2190:OE1 /H48   | 35%       |
|               | Glu2190:OE2 /H48   | 4%        |
|               | Val2240:HN /N18    | 100%      |
|               | Thr2245:HG1 /O1    | 7%        |
|               | Asp2357:OD1 /H48   | 27%       |
|               | Asp2357:OD2 /H48   | 4%        |
| Picrasidine M | Ser2165:HG1 /O36   | 2%        |
|               | Lys2187:HZ3 /N36   | 4%        |
|               | Trp2239:HE1 /O17   | 6%        |
|               | Val2240:HN /O17    | 29%       |
|               | Val2240:HN /O18    | 30%       |
|               | Thr2245:HG1 /O34   | 1%        |
|               | His2340:HE2 /O36   | 2%        |
|               | Ser2342:HG1 /O34   | 2%        |
|               | Asp2343:HD22 /N26  | 16%       |
|               | Asp2343:HD22 /O36  | 2%        |
| Acerosin      | Asp2195:OD2 /H42   | 38%       |
|               | Tyr2225:HH /O26    | 96%       |
|               | Trp2239:HE1 /O13   | 4%        |
|               | Trp2239:NE1 /H28   | 3%        |
|               | Val2240:HN /O12    | 10%       |
|               | Val2240:HN /O18    | 96%       |
|               | Asp2357:HN /O26    | 86%       |

H-bond occupancy cutoff: 0.3 nm.

MD simulation was employed to validate the stability of interactions between each ligand and mTOR protein in the docking poses from docking simulation.

2. Materials and Methods

2.1. Data Collection. The X-ray crystallography structure of the mammalian target of rapamycin (mTOR) was obtained from RCSB Protein Data Bank with PDB ID 4JSX [29]. To
predict the disordered residues in mTOR protein, PONDR-Fit [30] protocol was employed with the sequence from Swiss-Prot (UniProtKB: P42345). The X-ray crystallography structure of mTOR protein was prepared by Prepare Protein Module in Discovery Studio 2.5 (DS2.5) to remove crystal water and protonate the final structure with Chemistry at HARvard Macromolecular Mechanics (CHARMM) force field [31]. The TCM compounds from TCM Database@Taiwan [27] were prepared by Prepare Ligand Module in DS2.5 to protonate their final structures and filter by Lipinski’s rule of five [32]. The binding site for virtual screening was defined by the volume of the cocrystallized mTOR inhibitor, Torin2.

2.2. Docking Simulation. LigandFit protocol [33] in DS 2.5 was employed to redock cocrystallized mTOR inhibitor, Torin2, and dock the TCM compounds into the binding site defined above. The LigandFit protocol was performed using a shape filter and Monte-Carlo ligand conformation generation and then optionally minimized the docking poses with CHARMM force field [31]. Similar poses were filtered by the clustering algorithm. Each docking pose was evaluated by three scoring functions, -PLP1, -PLP2, and Dock Score.

2.3. Molecular Dynamics (MD) Simulation. Gromacs 4.5.5 [34] is a program used to perform the molecular dynamics (MD) simulation using classical molecular dynamics theory. In preparation section, the pdb2gmx protocol of Gromacs and the SwissParam program [35] were performed to provide topology and parameters of mTOR proteins with CHARMM27 force field and each ligand with CHARMM, respectively. For solvation, a cubic box was defined based upon the edge approximately 12 Å from the protein complexes periphery and solvated with TIP3P water model and 0.145 M NaCl model. For minimization, a maximum of 5,000 steps using steepest descents [36] minimization was employed to remove bad van der Waals contacts. Gromacs program utilizing position-restrained molecular dynamics with the Linear Constraint algorithm for the equilibration was performed with NVT equilibration, Berendsen weak thermal coupling method, and particle mesh Ewald method. For production, a total of 5000 ps production simulation with time step in unit of 2 fs was performed with NPT ensembles and particle mesh Ewald (PME) option. A series of protocols in Gromacs program was employed to analyze the MD trajectories.

3. Results and Discussion

3.1. Disordered Protein Prediction. The disordered disposition of residues in mTOR protein was predicted by PONDR-Fit protocol with the sequence of mTOR protein from Swiss-Prot (UniProtKB: P42345). As illustrated in Figure 1, the key residues in the binding site of mTOR protein were not laid in the disordered area (>0.5). It indicates that the mTOR protein...
Figure 4: Docking pose of mTOR protein complexes with (a) Torin2, (b) picrasidine M, and (c) acerosin.
expresses a stable binding domain in protein folding and is suitable for docking simulation.

3.2. Docking Simulation. To validate the accuracy of LigandFit protocol, the cocrystallized mTOR inhibitor, Torin2, was redocked into the binding site of mTOR protein. As root-mean-square deviation (RMSD) value between crystallized structure and docking pose of Torin2 is 0.5834 (Figure 2), LigandFit protocol is suitable for virtual screening with mTOR protein. After virtual screening, the chemical scaffold top TCM compounds ranked by Dock Score [33] and control, Torin2, are shown in Table 1. The top two TCM compounds, picrasidine M and acerosin, were extracted from Picrasma quassioides (D. Don) Benn. and Vitex negundo L. The chemical scaffold top TCM compounds and control are illustrated in Figure 3. According to the docking poses in Figure 4, the candidate compounds and Torin2 have hydrogen bonds (H-bonds) and \( \pi \) interactions with common residues Val2240 and Trp2239, respectively. In addition, they have hydrophobic contacts with residues Glu2190, Asp2195, Leu2185, Tyr2225, Ile2237, Gly2238, Trp2239, Val2240, Cys2243, Met2345, and Ile2356.

3.3. Molecular Dynamics Simulation. LigandFit protocol performed a docking simulation with a rigid body of mTOR proteins, so the conformation of the mTOR protein may modify under dynamic conditions. For this reason, MD simulation was performed to validate the stability of interactions between mTOR proteins and each ligand. The atomic fluctuations of mTOR proteins and ligands in protein complexes with picrasidine M, acerosin, and control were displayed in Figure 5. It shows that mTOR proteins tend to be stable after MD simulation. They indicate that the atoms of picrasidine M have a sharp fluctuation before the system tends to be stable. The variation of radii of gyration for protein and ligand over 5000 ps MD simulation was displayed in Figure 6. They show that the radii of gyration for mTOR protein complexes with ligand except picrasidine M have decreased after MD simulation. For the total energy of each protein complex, there is no significant variation during MD simulation (Figure 7). The variation of solvent accessible surface area over 5000 ps MD simulation shown in Figure 8 indicates that docking with picrasidine M, acerosin, and Torin2 would not affect the solvent accessible surface of mTOR protein under dynamic conditions.

To compare the variation of docking poses in docking simulation and after MD simulation, we identify the representative structures of mTOR protein complexes using the RMSD values and graphical depiction of the clusters analysis with a RMSD cutoff of 0.12 nm and illustrated the docking poses of the representative structures in Figure 9. The H-bond occupancy for key residues of mTOR protein with each ligand is listed in Table 2. For Torin2, it has stable H-bonds with residues Glu2190 and Val2240 and \( \pi \) interactions with residue Trp2239. For the TCM candidates, they also have stable H-bonds with residues Val2240 and \( \pi \) interactions with residue Trp2239 as Torin2, which indicate that they have similar docking pose and effects in mTOR protein.

4. Conclusion

This study aims to investigate the potent lead TCM candidates for mTOR protein inhibitors against Leigh syndrome and other mitochondrial disorders. The top TCM compounds, picrasidine M and acerosin, have higher binding affinities with target protein in docking simulation than control. There have H-bonds with residues Val2240, \( \pi \) interactions with common residue Trp2239, and hydrophobic contacts with residues Glu2190, Asp2195, Leu2185, Tyr2225, Ile2237, Gly2238, Trp2239, Val2240, Cys2243, Met2345, and Ile2356. After MD simulation, the top TCM compounds maintain similar docking poses under dynamic conditions as control. In addition, the top two TCM compounds, picrasidine M and acerosin, were extracted from Picrasma quassioides (D. Don) Benn. and Vitex negundo L. Hence, we propose the TCM compounds, picrasidine M and acerosin, as potential candidates as lead compounds for further study in drug development process with the mTOR protein against Leigh syndrome and other mitochondrial disorders.
Figure 6: Variation of radii of gyration for (a) protein and (b) ligands for mTOR protein complexes with Torin2, picrasidine M, and acerosin over 5000 ps of MD simulation.

Figure 7: (a) Distribution and (b) variation of total energy for mTOR protein complexes with Torin2, picrasidine M, and acerosin over 5000 ps of MD simulation.

Figure 8: Variation of (a) total solvent accessible surface area, (b) hydrophobic surface area, and (c) hydrophilic surface area for mTOR protein complexes with Torin2, picrasidine M, and acerosin over 5000 ps of MD simulation.
Figure 9: Left: root-mean-square deviation value (upper left half) and graphical depiction of the clusters with cutoff 0.12 nm (lower right half) and right: docking poses of middle RMSD structure in the major cluster for mTOR protein complexes with (a) Torin2, (b) picrasidine M, and (c) acerosin.
Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Kuan-Chung Chen, Wen-Yuan Lee, and Hsin-Yi Chen contributed equally to this work.

Acknowledgments

The research was supported by grants from the National Science Council of Taiwan (NSC102-2325-B039-001, NSC102-2221-E-468-027), Asia University (ASIA100-CMU-2, ASIA101-CMU-2, and 102-ASIA-07), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004), Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-003), and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan.

References

[1] S. B. Vafai and V. K. Mootha, “Mitochondrial disorders as windows into an ancient organelle,” Nature, vol. 491, no. 7424, pp. 374–383, 2012.
[2] S. Rahman, R. B. Blok, H. M. Dahl et al., “Leigh syndrome: clinical features and biochemical and DNA abnormalities,” Annals of Neurology, vol. 39, no. 3, pp. 343–351, 1996.
[3] S. B. Vafai and V. K. Mootha, “Medicine. A common pathway for a rare disease?” Science, vol. 342, no. 6165, pp. 1453–1454, 2013.
[4] N. Darin, A. Oldfors, A. Moslemi, E. Holme, and M. Tulinius, “The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities,” Annals of Neurology, vol. 49, no. 3, pp. 377–383, 2001.
[5] Y. M. Leung, K. L. Wong, S. W. Chen et al., “Down-regulation of voltage-gated Ca2+ channels in Ca2+ store-depleted rat insulinoma RINm5F cells,” BioMedicine, vol. 3, no. 3, pp. 130–139, 2013.
[6] Y. Jiang, X. Li, W. Yang et al., “PKM2 regulates chromosome segregation and mitosis progression of tumor cells,” Molecular Cell, vol. 53, no. 1, pp. 75–87, 2014.
[7] V. Janssens and J. Goris, “Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling,” Biochemical Journal, vol. 353, no. 3, pp. 417–439, 2001.
[8] M. A. Leissring, E. Malito, S. Hedouin et al., “Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin,” PLoS ONE, vol. 5, no. 5, Article ID e10504, 2010.
[9] K.-P. Su, “Inflammation in psychopathology of depression: clinical, biological, and therapeutic implications,” BioMedicine, vol. 2, no. 2, pp. 68–74, 2012.
[10] C.-L. Jao, S.-L. Huang, and K.-C. Hsu, “Angiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effects,” BioMedicine, vol. 2, no. 4, pp. 130–136, 2012.
[11] S. C. Johnson, M. E. Yanos, E. B. Kayser et al., “mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome,” Science, vol. 342, no. 6165, pp. 1524–1528, 2013.
[12] T. Geach, “Neurometabolic disease: treating mitochondrial diseases with mTOR inhibitors— a potential treatment for Leigh syndrome?” Nature Reviews Neurology, vol. 10, no. 1, article 2, 2014.
[13] S. C. Johnson, P. S. Rabinovitch, and M. Kaebellein, “MTOR is a key modulator of ageing and age-related disease,” Nature, vol. 493, no. 7432, pp. 338–345, 2013.
[14] F. J. Ramos, S. C. Chen, M. G. Garelick et al., “Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival,” Science Translational Medicine, vol. 4, no. 144, Article ID 144ra103, 2012.
[15] C. Y. Chen and C. Y. C. Chen, “Insights into designing the dual-targeted HER2/HSP90 inhibitors,” Journal of Molecular Graphics and Modelling, vol. 29, no. 1, pp. 21–31, 2010.
[16] S. C. Yang, S. S. Chang, H. Y. Chen, and C. Y. C. Chen, “Identification of potent EGFR inhibitors from TCM Database@Taiwan,” PLoS Computational Biology, vol. 7, no. 10, Article ID e1001289, 2012.
[17] Y. A. Tsou, K. C. Chen, H. C. Lin, S. Chang, and C. Y. Chen, “Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics study,” PLoS ONE, vol. 7, no. 11, Article ID e50087, 2012.
[18] K. C. Chen, S. S. Chang, F. J. Tsai, and C. Y. Chen, “Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?” Journal of Biomolecular Structure and Dynamics, vol. 31, no. 11, pp. 1219–1235, 2013.
[19] K. Chen, M. F. Sun, S. C. Yang et al., “Investigation into Potent Inflammation Inhibitors from traditional Chinese medicine,” Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011.
[20] K. C. Chen, S. S. Chang, H. J. Huang, T. Lin, Y. Wu, and C. Y. Chen, “Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine,” Journal of Biomolecular Structure and Dynamics, vol. 30, no. 6, pp. 662–683, 2012.
[21] K. C. Chen, K. W. Chang, H. Y. Chen, and C. Y. C. Chen, “Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?” Molecular BioSystems, vol. 7, no. 9, pp. 2711–2719, 2011.
[22] T. T. Chang, K. C. Chen, K. W. Chang et al., “In silico pharmacology suggests ginger extracts may reduce stroke risks,” Molecular BioSystems, vol. 7, no. 9, pp. 2702–2710, 2011.
[23] S. S. Chang, H. J. Huang, and C. Y. Chen, “Two birds with one stone? Possible dual-targeting HIN1 inhibitors from traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011.
[24] H. J. Huang, Y. R. Jian, and C. Y. C. Chen, “Traditional Chinese medicine application in HIV: an in silico study,” Journal of Biomolecular Structure and Dynamics, vol. 32, no. 1, pp. 1–12, 2014.
[25] W. L. Tou, S. S. Chang, C. C. Lee, and C. Y. Chen, “Drug design for neuropathic pain regulation from traditional Chinese medicine,” Scientific Reports, vol. 3, p. 844, 2013.
[26] K. C. Chen, Y. R. Jian, M. F. Sun, T. T. Chang, C. C. Lee, and C. Y. Chen, “Investigation of silent information regulator
1 Sirt1 agonists from traditional Chinese medicine,” *Journal of Biomolecular Structure and Dynamics*, vol. 31, no. 11, pp. 1207–1218, 2013.

[27] C. Y. C. Chen, “TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico,” *PLoS ONE*, vol. 6, no. 1, Article ID e15939, 2011.

[28] C. Y. Chen and W. I. Tou, “How to design a drug for the disordered proteins?” *Drug Discovery Today*, vol. 18, no. 19-20, pp. 910–915, 2013.

[29] H. Yang, D. G. Rudge, J. D. Koos, B. Vaidialingam, H. J. Yang, and N. P. Pavletich, “MTOR kinase structure, mechanism and regulation,” *Nature*, vol. 497, no. 7448, pp. 217–223, 2013.

[30] B. Xue, R. L. Dunbrack, R. W. Williams, A. K. Dunker, and V. N. Uversky, “PONDR-FIT: a meta-predictor of intrinsically disordered amino acids,” *Biochimica et Biophysica Acta—Proteins and Proteomics*, vol. 1804, no. 4, pp. 996–1010, 2010.

[31] B. R. Brooks, R. E. Brucoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, “CHARMM: a program for macromolecular energy minimization and dynamics calculations,” *Journal of Computational Chemistry*, vol. 4, no. 2, pp. 187–217, 1983.

[32] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” *Advanced Drug Delivery Reviews*, vol. 46, no. 1–3, pp. 3–26, 2001.

[33] C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, “LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites,” *Journal of Molecular Graphics and Modelling*, vol. 21, no. 4, pp. 289–307, 2003.

[34] B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl, “GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation,” *Journal of Chemical Theory and Computation*, vol. 4, no. 3, pp. 435–447, 2008.

[35] V. Zoete, M. A. Cuendet, A. Grosdidier, and O. Michielin, “SwissParam: a fast force field generation tool for small organic molecules,” *Journal of Computational Chemistry*, vol. 32, no. 11, pp. 2359–2368, 2011.

[36] R. Fletcher, *Optimization*, Academic Press, New York, NY, USA, 1969.